Voices
Aya Mohamed: Real-World Evidence Reveals a Treatment Gap in High-Risk HR+/HER2- Early Breast Cancer
Aya Mohamed/X

Aya Mohamed: Real-World Evidence Reveals a Treatment Gap in High-Risk HR+/HER2- Early Breast Cancer

Aya Mohamed, Medical Oncologist, Associate Lecturer of Medical Oncology, Member of ASCO, shared a post on X about a paper by H.S. Rugo et al. published in ESMO Open:

“ESMO Open, Real-world evidence.

In node-positive, high-risk HR+/HER2- early Breast Cancer (N=3,170):

• >50% of abemaciclib-eligible patients did NOT receive therapy.

• High-risk patients showed significantly worse iDFS, DRFS and OS.”

Aya Mohamed

Title: Exploring the treatment gap and outcome risks in patients with node-positive, high-risk, HR-positive, HER2-negative early breast cancer: analyses of real-world data.

Authors: S.M. Tolaney, S. Sammons, A. Sandoval-Leon, J. Cortes, A.M. Liepa, B.R. Grimes, D. He, Z.L. Cui, J. Roose, W. Gathirua-Mwangi, K. Moreira, J. O’Shaughnessy, P. Neven, S.R.D. Johnston, and H.S. Rugo.

You can read the full paper in ESMO Open.

Aya Mohamed

More posts featuring Aya Mohamed.

A. Sandoval-Leon A.M. Liepa Aya Mohamed B.R. Grimes cancer D. He H S Rugo J. Cortes J. O’Shaughnessy J. Roose K. Moreira OncoDaily Oncology P. Neven S. Sammons S.M. Tolaney S.R.D. Johnston W. Gathirua-Mwangi Z.L. Cui